Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANRS 177 DUETTO: 4-days-per-week vs 7-days-per-week dual antiretroviral therapy in virologically controlled HIV-1 infection
2020-003951-13Phase 3Completed
- Sponsor
- ANRS
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dolutegravir, lamivudine, rilpivirine, darunavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ANRS. Primary endpoint: Virological failure at week 48. Started Feb 2021; status: completed.
02
Drugs
dolutegravirlamivudinerilpivirinedarunavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2020-003951-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003951-13.